Elevation Pharmaceuticals
Developing a pipeline of improved aerosol drug products for the COPD patients.
Launch date
Market cap
-
Enterprise valuation
€391m (Public information from Aug 2012)
Marlborough Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$30.0m | Series A | ||
$17.0m | Series A | ||
N/A | $12.4m | Early VC | |
$30.0m | Series B | ||
$430m Valuation: $430m | Acquisition | ||
Total Funding | €81.3m |